Fresenius SE & Co. KGaA

Investor Presentation • Nov 21, 2012

MainFirst Conference ‒ "Growth prospects for German Excellence"

November 21, 2012

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA

Fresenius Group: Financial Results

Sales 5-year CAGR: 10%

EBIT5-year CAGR: 12%

Net Income5-year CAGR: 17%

Group financial results before APP-transaction-related special items

Fresenius Group: Attractive Long-term Shareholder Returns

19th consecutive dividend increase

Compounded annual total return 31.12.2001 – 28.09.2012

Source: Bloomberg; dividends reinvested

Fresenius Group: Financial Results

	1 l S a e s	2 E B I T	3 i N t e n c o m e
/ Q 3 2 1 1 -	€ 1 1 0 0 4 m ,	€ 2 2 2 4 m ,	€ 6 8 2 m
G h t t t t r o w a c o n s a n t e n a e s c u r r c y r	2 % 1	3 % 1	% 1 5
h l G t t t o a a c a r w u t c e n c a e s u r r y r	8 % 1	9 % 1	2 % 1

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care.

2Adjusted for one-time costs of €7 million (non-financing expenses) related to the offer to the shareholders of RHÖN-KLINIKUM AG.

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain of €34 million at Fresenius Medical Care and for one-time costs of €31 million related to the offer to the shareholders of RHÖN-KLINIKUM AG. 2011 before special items due to MEB and CVR accounting.

Fresenius Group: Financial Results by Business Segment

/ Q 3 2 1 1 -	i F e s e n s r u d i l C M e c a a e r	i F e s e n s r u b i K a	i F e s e n s r u l i H e o s	i F e s e n s r u d V a m e
l S a e s h G t o r w	\$ S 0 0 9 U 1 5 m , 1 8 %	€ 3 3 6 3 m , 1 4 %	€ 2 3 4 7 m , 2 0 %	€ 5 3 6 m 1 2 %
E B I T h G t o r w	\$ U S 1 6 5 9 m , 1 1 %	€ 7 0 0 m 1 4 %	€ 2 3 2 m 1 9 %	€ 2 4 m 9 %

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

Fresenius Kabi: Update Q1-3/12

• 9% organic sales growth excellent contribution from all regions
• Strong organic sales growth in Emerging Markets (e.g. China: +17%, South Korea +22%)
• U.S. I.V. drug shortage update Shortage list mid-October: 84 I.V. drugs; 24 marketed by Kabi (July: 94 I.V. drugs; 31 marketed by Kabi)
• 9 product launches YTD in the U.S.
• Fenwal closing expected in Q4

Fresenius Helios: Update Q1-3/12

• • Organic sales growth slightly above 2012 target range of 3-5%
• • Stable EBIT margin of 9.9% (PY: 10.0%) including major recent acquisitions
• • EBIT increase to 11.6% (+140bps) in established clinics
• • 2013 DRG-Inflator of 2.0% (2012: 1.48%) – highest increase since the introduction of the DRG system in 2003
• • Hospital transaction market update:
• Acquired hospital revenue 2012 YTD: >€500 m significantly exceeding FY/11 (~€365 m) and FY/10 (~€230 m)
• Projects >€100 m in revenue pending

Fresenius Vamed: Update Q1-3/12

• • Improved 2012 outlook - Sales and EBIT now expected at upper end of 5-10% range
• • Excellent Q3 order intake of €166 m – exceeding order intake in the first half of €156 m
• • H.C. Hospital Consulting in Italy performing above expectations – gaining market share in maintenance / technical management of medical equipment
• • Switzerland – new hospital service subsidiary and acquisition of HELIOS post-acute care clinic

Fresenius Group: Financial Outlook by Business Segment

		i P e o r v u s	N e w
i F r e s e n u s b i K a	1 l h S t a e s g o r w i E B I T m a r g n	9 % ~ 2 0 % 5 ~	f d i c o n m e r f i d c o n r m e
i F e s e n s r u l i H e o s	1 l h S t a e s g o r w E B I T	3 % 5 % – € 3 0 € 3 2 0 ( d ) 1 m m u p p e r e n –	f d i c o n m e r f d i c o n r m e
i F r e s e n u s d V a m e	l h S t a e s g o r w h E B I T t g r o w	5 % 1 0 % – % 0 % 5 1 –	d p p e e n u r d u p p e r e n
i F e s e n s r u i h B t o e c	E B I T	€ 2 € 3 0 5 m m ~ - – -	€ 2 5 m ~ -

1 organic

Fresenius Group: Financial Outlook Fully Confirmed

	i P e o s r v u	N e w
1 h R t e e n e g o v u r w t t t a c o n s a n c u r r e n c y	2 % % 1 1 4 –	f d i c o n m e r
2 h N i t t e n o m e g o c r w t t t a c o n s a n c u r r e n c y	1 4 % 1 6 % –	f d i o n m e c r
C a p e x	f l 5 % G o r o u p s a e s ~	f d i c o n r m e

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care.

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA – adjusted for a non-taxable investment gain (€34 million) and potential special charges (up to €17 million) at Fresenius Medical Care as well as for one-time costs (€31 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG.

Attachments

Fresenius Group: Profit and Loss Statement

€ m	/ Q 3 2 1	/ Q 3 2 1 1 -	h G Q t o r w	/ 3 2 1 Y Y o
			l t a c u a t r a e s	t t c o n s a n t r a e s
1 S l e a s	8 6 4 4 ,	0 0 1 4 1 ,	2 0 %	3 % 1
2 E B I T	7 8 4	2 2 2 4 ,	2 0 %	1 1 %
N i t t t e n e r e s	6 1 7 -	8 0 4 -	3 % 4 -	2 % 5 -
I t n c o m e a e s x	8 1 7 -	2 5 5 -	9 % -	0 %
3 N i t e n c o m e	2 4 8	6 8 2	2 3 %	1 5 %

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care.

2Adjusted for one-time costs of €7 million related to the offer to the shareholders of RHÖN-KLINIKUM AG.

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain of €34 million at Fresenius Medical Care and for one-time costs of €31 million related to the offer to the shareholders of RHÖN-KLINIKUM AG. 2011 before special items due to MEB and CVR accounting.

Page 14MainFirst Conference ‒"Growth prospects for German Excellence", Fresenius SE & Co. KGaA, Investor Relations © Copyright, November 21, 2012

Fresenius Group: Cash Flow

€ m	Q 3 / 2 1	L T M 1 i M a g n r	Q 3 / 1 1	L T M 1 i M a g n r	G h t o r w Y Y o
i h l O C F t p e a n g a s o r w	6 7 1	1 2 7 %	5 0 6	1 0 7 %	3 3 %
C ( ) t a p e x n e	2 0 6 -	4 6 % -	1 8 3 -	4 5 % -	1 3 % -
h l F C F r e e a s o w ( b f d d d d ) i i i i i t e o e a c q s o n s a n e n s r u v	4 6 5	8 1 %	3 2 3	6 2 %	4 4 %
( ) A i i i t t c q u s o n s n e	9 7 -		3 5 -		% 1 7 7 -
d d D i i v e n s	3 7 -		3 5 -		6 % -
h l F C F e e a s o r w ( f d d d d ) i i i i i t t a e r a c q u s o n s a n v e n s	3 3 1	5 6 % -	2 5 3	3 4 % -	3 1 %

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

Cash Flow Development LTM

€ m	O t p e a r	i C F n g	C ( ) t a p e n e x		1 C h l F F e e a s o r w
	/ L T M Q 1- 3 1 2	i L T M M a r g n	/ L T M Q 1- 3 1 2	i L T M M a r g n	/ L T M Q 1- 3 1 2	i L T M M a r g n
	5 6 4	1 2 9 %	( ) 1 8 7	( ) 4 3 %	3 7 7	8 6 %
	2 0 4	8 % 7	( 6 ) 1 5	( % ) 5 1	8 4	3 2 % 7
	3 6	4 5 %	( ) 8	( ) 1 0 %	2 8	3 5 %
/ Co te rp or a O he t r	0 1 -	/ n a	( 3 ) 1	/ n a	2 3 -	/ n a
l. C F M ex c	8 3 0	2 0 8 % 1	( ) 3 6 4	( ) % 4 4	6 6 4	2 6 % 4
Gr ou p	2 3 4 0 ,	1 2 7 %	( ) 8 4 7	( ) 4 6 %	1 4 9 3 ,	8 1 %

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

³Understated: 3.6% excluding €26 million of capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

1Pro forma Liberty Dialysis Holdings, Inc. and Damp Group

2Before one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG

Debt excludes Mandatory Exchangeable Bonds which came to maturity on August 14, 2011

Fresenius Kabi: Strong Organic Sales Growth

€ m	/ Q 3 2 1 1 -	/ Q 3 1 1 1 -	i O g a n c r G h t o r w
f h I i T n u s o n e r a p y	7 5 4	6 6 5	1 0 %
I. V D g s r u	1 2 7 3 ,	1 0 7 6 ,	1 1 %
l l C i i N i i t t n c a u r o n	9 8 4	8 5 5	1 1 %
d l / M i D i e c a e v c e s f h l T i T r a n s u s o n e c n o o g y	3 5 2	3 5 4	1 % -
l l T t o a s a e s	3 3 6 3 ,	2 9 5 0 ,	9 %

Fresenius Kabi: Strong Organic Sales Growth

€ m	/ Q 1 3 1 2 -	/ Q 1 3 1 1 -	i O r g a n c h G t r o w
E u r o p e	1 4 4 9 ,	1 3 6 0 ,	6 %
h N A i t o r m e r c a	9 1 0	7 5 5	1 0 %
f A i P i i s a a c c -	6 2 4	5 1 1	% 1 5
f i i / i L A A t a n m e c a c a r r	3 6 2	3 2 4	% 1 4
l l T t o a s a e s	3 3 6 3 ,	2 9 5 0 ,	9 %

Fresenius Kabi: Excellent EBIT Improvement

€ m	/ Q 3 2 1 1 -	/ Q 3 1 1 1 -	h G t o r w
E o p e u r M i a g n r	2 8 4 1 9 6 %	2 8 4 2 0. 9 %	0 %
h N A i t o m e c a r r M i g n a r	3 7 7 4 1. 4 %	2 8 8 3 8 1 %	3 1 %
f f / / A i P i i L i A i A i t s a a a n m e a a c c r c r c - M i a r g n	2 3 1 2 2 % 1.	6 9 1 2 0. 2 %	2 6 %
d C C R & D t t o r p o r a e a n o r p o r a e	1 7 4 -	1 2 8 -	3 6 % -
l T E B I T t o a	7 0 0	6 1 3	1 4 %
i M a r g n	2 0 8 %	2 0 8 %

Fresenius Helios: Ongoing Strong Sales and EBIT Growth

€ m	Q 3 / 1 1 2 -	Q 3 / 1 1 1 -	h G t r o w
l l T t o a s a e s	2 3 4 7 ,	1 9 5 0 ,	2 0 %
E B I T
b l h d l f l E i i i i t t s a s e c n c p o r o o M i a r g n	2 3 5 1 1. 6 %	9 1 5 1 0. 2 %	2 % 1
/ A i i i D i i t t t c q u s o n s v e s u r e s ( l d / d l d ) i t i i t i 1 < c o n s o a o n e c o n s o a o n y r	3 -	0
l T E B I T t o a i M a r g n	2 3 2 9 9 %	1 9 5 1 0 0 %	1 9 %

2012 adjusted for the transfer of a post-acute care clinic from Fresenius Helios to Fresenius Vamed

Fresenius Helios: 2011 Clinic Development Plan

		f i l i Y t e a s n p o o o r r
	1 <	1	2	3	4	5	5 >	l T t o a
f N l i i o. o c n c s	1	1	-	6	4	7	2 5	4 3
( ) R € e v e n u e m	1 6	3 4	-	1 8 3	2 7 1	1 7 2	1, 6 6 2	2, 3 3 6
T t a g e r
( ) E B I T D A i % m a g n r	-	3. 0	6. 0	9 0	1 2. 0	1 5. 0	1 5. 0
( ) E B I T D A € m	-	1. 0	-	1 6. 4	3 2. 5	2 5. 7	2 4 9 2	3 2 4 8
d R t e p o e r
( ) E B I T D A i % m a g n r	-	-2 6	-	2. 9	1 3. 2	1 1. 2	1 6. 9	1 4 4
( ) E B I T D A € m	-3 2	-0 9	-	3 5.	3 5. 7	9 2 1	2 8 0. 3	3 3 6. 4
f l N i i t t > o. o c n c s a r g e	-	-	-	3	2	3	1 5	2 3
f l N i i t t < o. o c n c s a r g e	-	1	-	3	2	4	0 1	2 0
S IFR

Page 22MainFirst Conference ‒"Growth prospects for German Excellence", Fresenius SE & Co. KGaA, Investor Relations © Copyright, November 21, 2012

Fresenius Helios: Performance Indicators

	/ Q 1 3 1 2 -	/ Q 1 3 1 1 -	h C a n g e
f h l N i t o o o s p a s l A t i i c u e c a r e c n c s - l P t- t i i o s a c u e c a r e c n c s -	7 2 0 5 2 2	1 6 5 4 5 2 0	1 1 % % 1 1 0 % 1
f b d N o o e s l A i i t c u e c a r e c n c s - P l i i t- t o s a c u e c a r e c n c s -	2 3 2 6 0 , 1 8, 6 8 9 4, 5 7 1	1 2 0 2 1 1 , 1 6, 6 9 0 3, 4 2 2	6 % 1 1 2 % 3 4 %
d A i i m s s o n s ( ) A i i t t t e a e n p a e n c u c r -	5 4 3, 3 1 3	4 7 2, 3 8 9	1 5 %
O c c p a n c u y P t- t o s a c e c a e u r -	8 5 %	7 9 %
l h f ( d ) A t t v e r a g e e n g o s a y a y s A t c u e c a r e - P t- t o s a c u e c a r e -	6. 7 2 7. 2	6. 7 2 9 6

1 Dec 31, 2011

Page 23MainFirst Conference ‒"Growth prospects for German Excellence", Fresenius SE & Co. KGaA, Investor Relations © Copyright, November 21, 2012

Fresenius Vamed: Sales Growth and EBIT in line with Expectations

€ m	/ Q 1 3 1 2 -	/ Q 1 3 1 1 -	h G t r o w
b j i P t o e c s n e s s r u	2 8 5	3 1 1	8 % -
b S i i e r v c e u s n e s s	2 5 1	1 6 9	4 9 %
l l T t o a s a e s	3 6 5	8 0 4	2 % 1
l T E B I T t o a	2 4	2 2	9 %
i M a r g n	4 5 %	4 6 %
1 O d i k t r e r n a e	3 2 2	3 3 5	4 % -
1 O d b k l r e r a c o g	8 8 7	2 8 4 5	4 %

1Project business only

2Dec 31, 2011

2012 adjusted for the transfer of a post-acute care clinic from Fresenius Helios to Fresenius Vamed

Share Information

Share key facts

Number of shares¹ 177,944,610Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Structure Sponsored Level I ADR

1as of September 30, 2012

Financial Calendar

• 26.02.2013 Report on Fiscal Year 2012
• 30.04.2013 Report on 1st quarter 2013
• 17.05.2013 Annual General Meeting, Frankfurt/Main
• 30.07.2013 Report on 1st half 2013
• 05.11.2013 Report on 1st ³rd quarter 2013

Contact

• Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485
• e-mail: Birgit.Grund@fresenius.com

For further information and current news: http://www.fresenius.com